Earnings & Valuation
This table compares Galera Therapeutics and Acerus Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Galera Therapeutics | N/A | N/A | -$59.08 million | ($0.10) | -0.23 |
| Acerus Pharmaceuticals | $2.12 million | 0.80 | -$33.82 million | ($3.57) | -0.06 |
Acerus Pharmaceuticals has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Institutional and Insider Ownership
50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Galera Therapeutics and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Galera Therapeutics | N/A | N/A | -99.34% |
| Acerus Pharmaceuticals | -924.33% | N/A | -74.62% |
Summary
Galera Therapeutics beats Acerus Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About Galera Therapeutics
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
About Acerus Pharmaceuticals
Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
